Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ryne Biotechnology
AddedFeb 15, 2024
UpdatedJun 18, 2026
Ryne Biotechnology

Ryne Biotechnology

Series A

Ryne Biotech, founded in 2022, pioneers off-the-shelf neuron therapies for neurodegenerative disorders.

HQ
San Diego, CA, US
Founded
2022
Overview
Compare
Fundraising
Employees

Ryne Biotechnology, founded in 2022 and based in Cambridge, Massachusetts, specializes in developing off-the-shelf neuron replacement therapies aimed at treating neurodegenerative movement disorders. The company's mission is to advance innovative treatments that can significantly improve patients' quality of life.

Ryne Biotechnology has made notable strides in the biotechnology sector by focusing on scalable and accessible therapeutic solutions. Their pioneering work in neuron replacement therapies positions them as a key player in the fight against neurodegenerative diseases.

Ryne Biotechnology - Similar Companies

Neuronity logo

Neuronity

neuronitytx.com

Neuron23 logo

Neuron23

Denali Therapeutics logo

Denali Therapeutics

Neuraly logo

Neuraly

neuralymed.com

Neurona Therapeutics logo

Neurona Therapeutics

Mahzi Therapeutics logo

Mahzi Therapeutics

mahzi.com

Escape Bio logo

Escape Bio

escapebio.com

Neuronascent logo

Neuronascent

neuronascent.com

CyThera logo

CyThera

Orphan Star Therapeutics logo

Orphan Star Therapeutics

CuraSen Therapeutics logo

CuraSen Therapeutics

curasen.com

Mitosense logo

Mitosense

mitosenseinc.com

Spinogenix logo

Spinogenix

spinogenix.com

NeuroTherapia logo

NeuroTherapia

neurotherapia.com

Therini Bio logo

Therini Bio

therinibio.com

Ryne Biotechnology - Quick Facts

Who are Ryne Biotechnology's competitors?

Companies similar to Ryne Biotechnology include Neuronity, Neuron23, Denali Therapeutics and Neuraly.

When was Ryne Biotechnology founded?

Ryne Biotechnology was founded in 2022.

Where is Ryne Biotechnology's headquarters located?

Ryne Biotechnology's headquarters is located in San Diego, CA, US.

When was Ryne Biotechnology's last funding round?

Ryne Biotechnology's most recent funding round was for $4M (USD) in February 2023.

How much has Ryne Biotechnology raised to-date?

As of Feb 14, 2023, Ryne Biotechnology has raised a total of $7M (USD).

How many employees does Ryne Biotechnology have?

Ryne Biotechnology has 7 employees as of Feb 5, 2024.

Ryne Biotechnology - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Main Product
  • Neuron Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified